吉林敖东(000623.SZ)：预计2025年净利润同比增长46%～60%

Core Viewpoint - Jilin Aodong (000623.SZ) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 2.265 billion to 2.482 billion yuan, representing a growth of 46.00% to 60.00% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is projected to be between 2.265 billion and 2.482 billion yuan, with a year-on-year growth of 46.00% to 60.00% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 2.069 billion and 2.287 billion yuan, reflecting a growth of 31.56% to 45.37% year-on-year [1] - The impact of non-recurring gains and losses on net profit is estimated to be approximately 195.6893 million yuan for 2025, compared to -21.5112 million yuan in the same period of 2024 [1] Strategic Focus - The company is focusing on value management and enhancing operational quality, adhering to its corporate values of "focusing on people and specializing in medicine" [1] - The implementation of a sales-driven policy centered on "large product groups and multiple product groups" is a key strategy for growth [1] - The company is pursuing a dual-driven development model of "pharmaceutical health + financial capital" to accelerate its growth [1]